EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 212 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Spending Review 2020 – Steps in the right direction, but opportunities... November 25, 2020 Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who... June 4, 2024 Keanu Reeves Has A Long History Of Supporting Cancer Research January 13, 2022 Darolutamide Delays the Spread of Some Prostate Cancers March 15, 2019 Load more HOT NEWS COVID-19 in people with cancer – what we know so far FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma 10 Tips for National Cancer Prevention Month
